Educational Activities

Show Filters
Hide Filters
1-5 of 5 Activities
Title
Availability
Format
Credits
Course Opens
Buttons

Breaking the Cycle in Cardiorenal Anemia Syndrome: The Practice-changing Role of IV Iron at the CKD–Heart Failure Interface

All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies.

1.00
08/15/2022

Javed Butler, MD, MPH, MBA

President, Baylor Scott and White Research Institute, Dallas, TX
Distinguished Professor of Medicine
University of Mississippi, Jackson, MS

Javed Butler, MD, MPH, MBA

President, Baylor Scott and White Research Institute, Dallas, TX
Distinguished Professor of Medicine
University of Mississippi, Jackson, MS

Matthew R. Weir, MD

Director, Division of Nephrology
Professor of Medicine
University of Maryland Medical System, Baltimore, MD

Matthew R. Weir, MD

Director, Division of Nephrology
Professor of Medicine
University of Maryland Medical System
Baltimore, MD

Breaking the Cycle in Cardiorenal Anemia Syndrome: The Practice-changing Role of IV Iron at the CKD–Heart Failure Interface

All clinicians managing patients with non-dialysis-dependent chronic kidney disease or heart failure must be aware of the deleterious impacts of concomitant anemia and the established, emerging, and practice-changing role of intravenous (IV) iron therapies.

1.0
08/15/2022

Javed Butler, MD, MPH, MBA

President, Baylor Scott and White Research Institute, Dallas, TX
Distinguished Professor of Medicine
University of Mississippi, Jackson, MS

Javed Butler, MD, MPH, MBA

President, Baylor Scott and White Research Institute, Dallas, TX
Distinguished Professor of Medicine
University of Mississippi, Jackson, MS

Matthew R. Weir, MD

Director, Division of Nephrology
Professor of Medicine
University of Maryland Medical System, Baltimore, MD

Matthew R. Weir, MD

Director, Division of Nephrology
Professor of Medicine
University of Maryland Medical System
Baltimore, MD

New Horizons in Unresectable Stage III NSCLC: A Case-based Exploration of Evolving Data and the Emergence of Immunotherapy

Join our Expert Faculty, Drs. Joel W. Neal, MD, PhD and Victoria Sherry, DNP, CRNP, AOCNP as they discuss treatment principles across the continuum of care in unresectable, stage III NSCLC.

1.0
09/23/2022

Joel W. Neal, MD, PhD

Associate Professor of Medicine, Division of Oncology
Medical Director for the Cancer Clinical Trials Office
Medical Director of Informatics Stanford Cancer Center Stanford, CA

Joel W. Neal, MD, PhD

Associate Professor of Medicine, Division of Oncology
Medical Director for the Cancer Clinical Trials Office
Medical Director of Informatics Stanford Cancer Center Stanford, CA

Victoria Sherry, DNP, CRNP, AOCNP

Oncology Nurse Practitioner for Thoracic Malignancies
Abramson Cancer Center
Philadelphia, PA

Victoria Sherry, DNP, CRNP, AOCNP

Oncology Nurse Practitioner for Thoracic Malignancies
Abramson Cancer Center
Philadelphia, PA

New Horizons in Unresectable Stage III NSCLC: A Case-based Exploration of Evolving Data and the Emergence of Immunotherapy

Join our Expert Faculty, Drs. Joel W. Neal, MD, PhD and Victoria Sherry, DNP, CRNP, AOCNP as they examine the established treatment landscape for unresectable, stage III NSCLC, as well as the emerging role of immunotherapy, and practical clinical considerations for anticipating, mitigating, and managing immune-related adverse events.

1.0
09/23/2022

Joel W. Neal, MD, PhD

Associate Professor of Medicine, Division of Oncology
Medical Director for the Cancer Clinical Trials Office
Medical Director of Informatics Stanford Cancer Center Stanford, CA

Joel W. Neal, MD, PhD

Associate Professor of Medicine, Division of Oncology
Medical Director for the Cancer Clinical Trials Office
Medical Director of Informatics Stanford Cancer Center Stanford, CA

Victoria Sherry, DNP, CRNP, AOCNP

Oncology Nurse Practitioner for Thoracic Malignancies
Abramson Cancer Center
Philadelphia, PA

Victoria Sherry, DNP, CRNP, AOCNP

Oncology Nurse Practitioner for Thoracic Malignancies
Abramson Cancer Center
Philadelphia, PA

Navigating Novel Terrain in Anemia of Chronic Kidney Disease: A Patient-centric Review of Disease State, Current Chasms in Care, and the Future Promise of HIF-PH Inhibition

To facilitate timely diagnosis and rapid treatment initiation for anemia in CKD, the multidisciplinary and interprofessional CKD-anemia treatment team should be aware of the significant impact of anemia on patient quality of life, progression of CKD, and cardiovascular events.

1.00
09/28/2022

Calvin J. Meaney, PharmD, BCPS

Clinical Associate Professor and Vice Chair for Research
Department of Pharmacy Practice
School of Pharmacy and Pharmaceutical Sciences
University at Buffalo, Buffalo, NY

Calvin J. Meaney, PharmD, BCPS

Clinical Associate Professor and Vice Chair for Research
Department of Pharmacy Practice
School of Pharmacy and Pharmaceutical Sciences
University at Buffalo, Buffalo, NY

Jane S. Davis, DNP, CRNP

Nephrology
University of Alabama at Birmingham
Birmingham, AL

Jane S. Davis, DNP, CRNP

Nephrology
University of Alabama at Birmingham
Birmingham, AL

Ajay K. Singh, MBBS, FRCP, MBA

Senior Associate Dean for Postgraduate Medical Education
Director, Master in Medical Sciences in Clinical Investigation (MMSCI) program, Harvard Medical School
Physician, Renal Division
Brigham and Women's Hospital/ Dana Farber Cancer Institute, Boston, MA

Ajay K. Singh, MBBS, FRCP, MBA

Senior Associate Dean for Postgraduate Medical Education
Director, Master in Medical Sciences in Clinical Investigation (MMSCI) program, Harvard Medical School
Physician, Renal Division
Brigham and Women’s Hospital/ Dana Farber Cancer Institute, Boston, MA